斯里兰卡南部选定医院下呼吸道感染治疗(TREAT-SL):阶梯楔形整群随机临床试验研究方案
本研究为前瞻性、开放标签、阶梯楔形整群随机试验,在斯里兰卡南部三家公立医院开展,纳入765例≥14岁因下呼吸道感染住院的患者,评估电子临床决策支持工具(eCDST)RespiQuestAB对下呼吸道感染管理的影响。主要结局为指数就诊时抗菌药物处方时长和30天内下呼吸道感染恶化复合临床结局。
要点
- eCDST整合实时流感发生率与临床预测因子估算下呼吸道感染病因概率。
- eCDST基于诊断概率提供抗菌药物和抗病毒(奥司他韦)治疗推荐。
- 共主要结局为抗菌药物处方时长和30天恶化复合临床结局。
核心结论
- 该试验旨在确定eCDST对斯里兰卡南部下呼吸道感染管理的影响。
研究设计与样本
- 前瞻性、开放标签、阶梯楔形整群随机试验,在斯里兰卡南部三家公立医院开展。
- 计划纳入765例年龄≥14岁因下呼吸道感染住院的患者,分布在9个整群中,每个整群由一对病房(1间男性病房和1间女性病房)组成。
关键数值与推荐
- RespiQuestAB估算流感、其他病毒(包括SARS-CoV-2)感染、细菌感染、非感染性疾病或不确定诊断的概率。
- 若阳性结果使相关诊断概率增加至少5%,推荐进行流感、SARS-CoV-2、肺炎链球菌或降钙素原的即时检验(POC)。
- 共同主要结局为指数就诊时抗菌药物处方时长和30天内下呼吸道感染恶化复合临床结局。
- 次要结局包括复合结局的单个临床结局、抗菌药物和抗病毒处方的接受与时长、医生对RespiQuestAB推荐的诊断检测和治疗的依从性。
- 探索性结局包括意愿结局排名(DOOR)水平(按有序量表排列)、单个DOOR水平以及SARS-CoV-2免疫调节治疗的处方。
临床怎么用
- 医生在手机上使用RespiQuestAB,根据诊断概率获取抗菌药物和抗病毒(奥司他韦)治疗推荐。
- 医生可独立开具RespiQuestAB推荐的即时检验,也可在推荐时开具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lower respiratory tract infection (LRTI) is a leading cause of hospitalization and antibacterial use globally. In low- and middle-income countries (LMICs), limited diagnostic resources contribute to inappropriate antibacterial use for LRTI. The aim of this trial is to determine the impact of an electronic clinical decision support tool (eCDST) on LRTI management in Southern Sri Lanka. METHODS: This is a prospective, open-label, stepped-wedge, cluster-randomized trial that will be conducted at three public hospitals. A total of 765 patients aged ≥ 14 years who are hospitalized with LRTI will be enrolled across 9 clusters; each cluster consists of a pair of wards (1 male and 1 female). The intervention consists of implementing an eCDST (RespiQuestAB) that physicians use on their mobile phones. RespiQuestAB integrates real-time influenza incidence in Sri Lanka with epidemiological and clinical predictors of LRTI etiology to estimate the probability of the following diagnoses: influenza, other viral (including SARS-CoV-2) infection, bacterial infection, noninfectious condition, or indeterminate. Point-of-care (POC) tests for influenza, SARS-CoV-2, Streptococcus pneumoniae, or procalcitonin are recommended if a positive result increases the probability of the associated diagnosis by at least 5%; clinicians may also order these tests independently. RespiQuestAB provides treatment recommendations regarding antibacterial and antiviral (oseltamivir) use based on the probability of diagnosis. Participants will be followed longitudinally to assess antibacterial prescription and clinical outcomes. The co-primary outcomes are as follows: (1) Duration of antibacterial prescription for the index visit and (2) a composite clinical outcome associated with worsening LRTI by day 30. Secondary outcomes include the individual clinical outcomes of the composite outcome, receipt, and duration of antibacterial and antiviral prescriptions and physician adherence to diagnostic tests and treatments recommended by RespiQuestAB. Exploratory outcomes include Desirability of Outcome Ranking (DOOR) level arranged in an ordinal scale, individual DOOR levels, and prescription of immunomodulatory therapy for SARS-CoV-2. DISCUSSION: Results of this clinical trial will provide information on the impact of the RespiQuestAB on antibacterial use and clinical outcomes among patients with LRTI in an LMIC setting. TRIAL REGISTRATION: ClinicalTrials.gov NCT06331364. Registered on March 25, 2024.
引用
- De Zoysa PDWD, Weerasinghe SA, Gamage J, et al. TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): study protocol for a stepped-wedge, cluster-randomized clinical trial. Trials. 2026. PMID: 41851897. doi:10.1186/s13063-026-09628-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。